Structure Therapeutics Inc. Forecasted to Post Q1 2024 Earnings of ($0.20) Per Share (NASDAQ:GPCR)

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Investment analysts at Lifesci Capital issued their Q1 2024 earnings per share (EPS) estimates for Structure Therapeutics in a note issued to investors on Monday, April 1st. Lifesci Capital analyst M. Belghiti expects that the company will post earnings of ($0.20) per share for the quarter. Lifesci Capital has a "Outperform" rating on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.96) per share. Lifesci Capital also issued estimates for Structure Therapeutics' Q2 2024 earnings at ($0.20) EPS, Q3 2024 earnings at ($0.19) EPS, Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.93) EPS.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR traded up $0.54 during midday trading on Wednesday, reaching $40.06. 232,899 shares of the company's stock traded hands, compared to its average volume of 599,897. The company has a market cap of $1.87 billion and a price-to-earnings ratio of -48.27. Structure Therapeutics has a one year low of $21.79 and a one year high of $75.02. The stock has a 50 day moving average of $41.83 and a 200 day moving average of $48.46.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently bought and sold shares of GPCR. Wellington Management Group LLP increased its position in Structure Therapeutics by 404.0% in the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company's stock worth $178,216,000 after buying an additional 3,504,747 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Structure Therapeutics by 498.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 427,735 shares of the company's stock worth $17,434,000 after buying an additional 356,302 shares in the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in Structure Therapeutics in the fourth quarter worth about $475,000. FIL Ltd increased its position in Structure Therapeutics by 8.1% in the fourth quarter. FIL Ltd now owns 9,304 shares of the company's stock worth $379,000 after buying an additional 695 shares in the last quarter. Finally, Exome Asset Management LLC purchased a new stake in Structure Therapeutics in the fourth quarter worth about $2,776,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.